Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Operating Expenses

Last Annual Value

7.39M

3-Year CAGR

19%

5-Year CAGR

33%

10-Year CAGR

167%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Operating Expenses

NTRB · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
7.39M
8.8%10.8%47.5% 
143.27M
7.8%19.5%N/A
59.10M
-17.1%-14.0%23.4%
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
54.00M
12.9%7.5%0.2%
82.76M
7.5%38.6%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
115.73M
-8.7%10.2%220.9%
18.62M
-5.9%22.3%N/A
25.74M
-11.5%10.4%31.5%
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
219.18M
36.5%54.5%19.7%
IMA logo
ImageneBio Inc
NASDAQ:IMA
48.22M
-16.7%21.8%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
103.23M
1.3%2.4%9.6%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15